Shares of Tilray (TLRY) fell 5.93% to $20.16 at 15:22 EST on Thursday, after three sequential sessions in a row of gains. NASDAQ Composite (TLRY) is rising 0.73% to $14,012.85, following the last session’s downward trend, This seems, up to now, a somewhat positive trend trading session today.
Tilray’s last close was $21.43, 68.01% below its 52-week high of $67.00.
Today’s last reported volume for Tilray is 30011841 which is 15.69% above its average volume of 25941128.
The company’s growth estimates for the ongoing quarter is 89.2% and a drop 50% for the next.
Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 611.06M for the twelve trailing months.
Tilray’s last week, last month’s, and last quarter’s current volatility was 7.85%, 1.14%, and 4.93%, respectively.
Tilray’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.85% (last week), 4.49% (last month), and 4.93% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Tilray’s stock is considered to be oversold (<=20).
Tilray’s Stock Yearly Top and Bottom Value
Tilray’s stock is valued at $20.16 at 15:22 EST, way below its 52-week high of $67.00 and way higher than its 52-week low of $4.41.
Tilray’s Moving Average
Tilray’s value is way above its 50-day moving average of $16.78 and way higher than its 200-day moving average of $18.29.
Previous days news about Tilray (TLRY)
Tilray launching new medical marijuana brand. According to The Motley Fool on Tuesday, 8 June, "Our industry is only in the early stages of creating and bringing to market cannabinoid medicine options that meet patient needs," the company quoted Tilray Canada president Jim Meiers as saying. ", "In late-afternoon trading on Tuesday, Tilray shares were up by slightly more than 2%, outpacing the S&P 500’s 0.1% gain."
Tilray looks to keep growing now that its merger with Aphria has closed. According to InvestorPlace on Wednesday, 9 June, "As the Canadian cannabis market grows, which it inevitably will, Tilray will benefit as well. ", "Finance, Canaccord Genuity initiated its coverage on Tilray with a Buy on May 6. "
More news about Tilray (TLRY).